Cargando…
Differential SPARC mRNA expression in Barrett's oesophagus
Barrett's oesophagus (BE) is the precursor lesion to adenocarcinoma of the oesophagus. Understanding of the molecular alterations in this multistage process may contribute to improved diagnosis and treatment. Secreted protein acidic and rich in cysteine (SPARC) is a matricellular protein that m...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2003
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394336/ https://www.ncbi.nlm.nih.gov/pubmed/14562024 http://dx.doi.org/10.1038/sj.bjc.6601324 |
_version_ | 1782155391936757760 |
---|---|
author | Brabender, J Lord, R V Metzger, R Park, J Salonga, D Danenberg, K D Danenberg, P V Hölscher, A H Schneider, P M |
author_facet | Brabender, J Lord, R V Metzger, R Park, J Salonga, D Danenberg, K D Danenberg, P V Hölscher, A H Schneider, P M |
author_sort | Brabender, J |
collection | PubMed |
description | Barrett's oesophagus (BE) is the precursor lesion to adenocarcinoma of the oesophagus. Understanding of the molecular alterations in this multistage process may contribute to improved diagnosis and treatment. Secreted protein acidic and rich in cysteine (SPARC) is a matricellular protein that modulates cell adhesion and growth. Alterations in SPARC expression have been observed in a variety of solid tumours. The aim of this study was to assess the prevalence and timing of SPARC mRNA expression in Barrett's multistage disease and to investigate the impact of SPARC alterations on the development and progression of this disease. SPARC mRNA expression was measured using a quantitative real-time RT–PCR method in 108 specimens from 19 patients with BE without carcinoma, 20 patients with Barrett's-associated adenocarcinoma (EA), and a control group (CG) of 10 patients without evidence of gastro-oesophageal reflux disease. The median SPARC mRNA expression was significantly upregulated in BE tissues compared to paired normal oesophagus (NE) tissues for the BE group (P=0.004) and for the EA group (P<0.001). The SPARC mRNA expression was significantly higher in adenocarcinoma of the oesophagus compared to matching NE tissue and compared to Barrett's tissues in the EA group (P<0.001). Furthermore, SPARC expression values were significantly different between metaplastic and dysplastic Barrett's tissues (P=0.014). In histologically normal squamous oesophagus tissues obtained from carcinoma patients (EA group), the SPARC mRNA expression was significantly higher compared to NE mucosa from the BE group and the CG group (P=0.03). These findings suggest that the upregulation of SPARC mRNA expression is an early event in the development and progression of BE and EA, and that high SPARC expression may be a clinically useful biomarker for the detection of occult adenocarcinoma, and that a widespread ‘field effect’ is present in the NE of patients with oesophageal adenocarcinoma. |
format | Text |
id | pubmed-2394336 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2003 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-23943362009-09-10 Differential SPARC mRNA expression in Barrett's oesophagus Brabender, J Lord, R V Metzger, R Park, J Salonga, D Danenberg, K D Danenberg, P V Hölscher, A H Schneider, P M Br J Cancer Molecular and Cellular Pathology Barrett's oesophagus (BE) is the precursor lesion to adenocarcinoma of the oesophagus. Understanding of the molecular alterations in this multistage process may contribute to improved diagnosis and treatment. Secreted protein acidic and rich in cysteine (SPARC) is a matricellular protein that modulates cell adhesion and growth. Alterations in SPARC expression have been observed in a variety of solid tumours. The aim of this study was to assess the prevalence and timing of SPARC mRNA expression in Barrett's multistage disease and to investigate the impact of SPARC alterations on the development and progression of this disease. SPARC mRNA expression was measured using a quantitative real-time RT–PCR method in 108 specimens from 19 patients with BE without carcinoma, 20 patients with Barrett's-associated adenocarcinoma (EA), and a control group (CG) of 10 patients without evidence of gastro-oesophageal reflux disease. The median SPARC mRNA expression was significantly upregulated in BE tissues compared to paired normal oesophagus (NE) tissues for the BE group (P=0.004) and for the EA group (P<0.001). The SPARC mRNA expression was significantly higher in adenocarcinoma of the oesophagus compared to matching NE tissue and compared to Barrett's tissues in the EA group (P<0.001). Furthermore, SPARC expression values were significantly different between metaplastic and dysplastic Barrett's tissues (P=0.014). In histologically normal squamous oesophagus tissues obtained from carcinoma patients (EA group), the SPARC mRNA expression was significantly higher compared to NE mucosa from the BE group and the CG group (P=0.03). These findings suggest that the upregulation of SPARC mRNA expression is an early event in the development and progression of BE and EA, and that high SPARC expression may be a clinically useful biomarker for the detection of occult adenocarcinoma, and that a widespread ‘field effect’ is present in the NE of patients with oesophageal adenocarcinoma. Nature Publishing Group 2003-10-20 2003-10-14 /pmc/articles/PMC2394336/ /pubmed/14562024 http://dx.doi.org/10.1038/sj.bjc.6601324 Text en Copyright © 2003 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Molecular and Cellular Pathology Brabender, J Lord, R V Metzger, R Park, J Salonga, D Danenberg, K D Danenberg, P V Hölscher, A H Schneider, P M Differential SPARC mRNA expression in Barrett's oesophagus |
title | Differential SPARC mRNA expression in Barrett's oesophagus |
title_full | Differential SPARC mRNA expression in Barrett's oesophagus |
title_fullStr | Differential SPARC mRNA expression in Barrett's oesophagus |
title_full_unstemmed | Differential SPARC mRNA expression in Barrett's oesophagus |
title_short | Differential SPARC mRNA expression in Barrett's oesophagus |
title_sort | differential sparc mrna expression in barrett's oesophagus |
topic | Molecular and Cellular Pathology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394336/ https://www.ncbi.nlm.nih.gov/pubmed/14562024 http://dx.doi.org/10.1038/sj.bjc.6601324 |
work_keys_str_mv | AT brabenderj differentialsparcmrnaexpressioninbarrettsoesophagus AT lordrv differentialsparcmrnaexpressioninbarrettsoesophagus AT metzgerr differentialsparcmrnaexpressioninbarrettsoesophagus AT parkj differentialsparcmrnaexpressioninbarrettsoesophagus AT salongad differentialsparcmrnaexpressioninbarrettsoesophagus AT danenbergkd differentialsparcmrnaexpressioninbarrettsoesophagus AT danenbergpv differentialsparcmrnaexpressioninbarrettsoesophagus AT holscherah differentialsparcmrnaexpressioninbarrettsoesophagus AT schneiderpm differentialsparcmrnaexpressioninbarrettsoesophagus |